MINMON试验中丙型肝炎病毒简化监测治疗后的再感染及耐药相关替代突变
ACTG A5360(MINMON)试验评估丙型肝炎病毒简化治疗后的再感染率及基线耐药相关替代突变对持续病毒学应答的影响。397例参与者中,再感染率为3.9/100人年(95%CI 2.4-6.2),总体持续病毒学应答率为97.0%(95%CI 94.8-98.3);基线NS5A耐药相关替代突变与持续病毒学应答无显著差异。
要点
- 再感染率为3.9/100人年(95%CI 2.4-6.2),17例再感染者均为男性,其中13例为MSM、15例合并HIV。
- 排除再感染后,总体持续病毒学应答率为97.0%(95%CI 94.8-98.3)。
- 基线耐药相关替代突变存在与缺失时持续病毒学应答率分别为93.5%(43/46)和97%(337/346),无显著差异。
核心结论
- 计入再感染后,MINMON试验的持续病毒学应答率为97.0%,进一步支持简化丙型肝炎治疗。
- 基线韦帕他韦耐药相关替代突变对持续病毒学应答无显著差异。
- 再感染率较高,尤其在合并HIV的男男性行为者(MSM)中,强调需扩大循证干预以减少再感染。
研究设计与样本
- ACTG A5360(MINMON)试验,在入组后第0、24(持续病毒学应答访视)、48和72周安排HCV RNA检测。
- 入组后HCV RNA≥定量下限的参与者接受NS5A和NS5B基因深度测序,并用系统发育分析区分再感染与治疗失败。
- 397例参与者有入组后HCV RNA检测结果。
主要发现
- 397例参与者中,29例入组后HCV RNA≥定量下限且有可用测序数据。
- 29例中,5例初始判定为非持续病毒学应答、12例初始达到持续病毒学应答(第24周评估)后被确定为再感染,共17例再感染,再感染率为3.9/100人年(95%CI 2.4-6.2)。
- 17例再感染者均为男性,其中13例为MSM、15例合并HIV。
- 29例HCV RNA≥定量下限者中,12例被确定为治疗失败。
- 基线耐药相关替代突变存在与缺失时持续病毒学应答率(排除再感染)分别为93.5%(43/46)和97%(337/346),总体持续病毒学应答率为97.0%(95%CI 94.8-98.3)(385/397)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Simplified approaches to hepatitis C virus (HCV) treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial. METHODS: HCV RNA evaluations were scheduled at weeks 0, 24 (sustained viral response [SVR] visit), 48, and 72. Participants with post-entry HCV RNA ≥ lower limit of quantification (LLoQ) had deep sequencing of NS5A and NS5B genes performed. Phylogenetic analysis distinguished between reinfection and treatment failure. Reinfection rates per 100 person-years (PYS) were calculated with 95% confidence interval (CI) constructed using Poisson distribution. RESULTS: Of 397 participants with post-entry HCV RNA, 29 had ≥LLoQ and available sequencing data. Of those 29, 5 participants initially designated as non-SVR, and 12 participants initially attaining SVR (evaluated at week 24) were determined to have reinfections (total 17 reinfections) (reinfection rate 3.9/100 PYS [95% CI, 2.4-6.2]). All 17 participants with HCV reinfection were male (13 MSM and 15 with HIV). Of 29 had ≥LLoQ, 12 were identified as treatment failure. SVR (excluding reinfections) in presence and absence of baseline RAS was 93.5% (43/46) and 97% (337/346), respectively, with an overall SVR rate of 97.0% [95% CI, 94.8-98.3] (385/397). CONCLUSIONS: Accounting for reinfections, SVR in MINMON was 97.0% further supporting simplified HCV treatment. No significant difference in SVR was found by baseline velpatasvir RAS. The high reinfection rate, especially among men who have sex with men (MSM) with human immunodeficiency virus (HIV), underscores the need to scale-up evidence-based interventions to reduce reinfection. CLINICAL TRIALS REGISTRATION: NCT03512210.
引用
- Han WM, Solomon SS, Smeaton L, et al. Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial. Clin Infect Dis. 2025. PMID: 39702964. doi:10.1093/cid/ciae627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。